口服三氧化二砷在急性早幼粒细胞白血病患者中的药代动力学与安全性研究
SY-2101是新型口服三氧化二砷(ATO)制剂。这项1期研究在15例急性早幼粒细胞白血病(APL)患者中评估SY-2101与静脉ATO单次及多次给药后的药代动力学、安全性和耐受性,以及食物对SY-2101药代动力学的影响。结果显示空腹状态下SY-2101基于活性代谢物亚砷酸的全身暴露与静脉ATO相当,SY-2101可随餐或空腹给药,耐受性良好,大多数不良事件为低级别。
要点
- 空腹SY-2101与静脉ATO的AUC0-last和AUC0-inf几何均值比均为1.00,Cmax几何均值比为0.76。
- SY-2101餐后与空腹相比AUC0-last、AUC0-inf和Cmax几何均值比分别为1.08、1.12和0.85,可随餐或空腹给药。
- SY-2101耐受性良好,大多数不良事件为低级别。
核心结论
- 本研究提供了首个直接比较SY-2101与静脉ATO的患者内药代动力学交叉结果,支持两种制剂临床等效的可能性。
研究设计与样本
- 这项1期研究在15例急性早幼粒细胞白血病患者中评估SY-2101与静脉ATO单次及多次给药后的药代动力学、安全性和耐受性,以及食物对SY-2101药代动力学的影响。
- 试验注册号为NCT04996030。
主要发现
- 空腹状态下SY-2101基于活性代谢物亚砷酸[As(III)]的全身暴露与静脉ATO相当,SY-2101与静脉ATO的AUC0-last和AUC0-inf几何均值比均为1.00。
- SY-2101与静脉ATO的Cmax几何均值比为0.76,原文指出这因给药途径不同而在预期之中。
- SY-2101餐后与空腹相比,AUC0-last、AUC0-inf和Cmax的几何均值比分别为1.08、1.12和0.85。
- SY-2101耐受性良好,大多数不良事件为低级别。
关键数值与推荐
- 空腹SY-2101与静脉ATO的AUC0-last几何均值比为1.00,AUC0-inf几何均值比为1.00,Cmax几何均值比为0.76。
- SY-2101餐后与空腹的AUC0-last几何均值比为1.08,AUC0-inf几何均值比为1.12,Cmax几何均值比为0.85。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SY-2101 is a novel oral formulation of arsenic trioxide (ATO). Although IV ATO in combination with all trans retinoic acid is highly efficacious in treating acute promyelocytic leukemia (APL), there remains a significant unmet need due to the treatment burden associated with receiving daily ATO infusions for nearly a year and the risk of complications associated with indwelling central catheters. The pharmacokinetics (PK), safety, and tolerability of SY-2101 and ATO IV after single- and multiple-dose administration and the impact of food on PK for SY-2101 were evaluated in this phase 1 study in 15 participants with APL. SY-2101 in the fasted state demonstrated comparable systemic exposure to ATO IV based on the active metabolite arsenious acid [As(III)], with geometric mean ratios (GMRs) of SY-2101 to ATO IV of 1.00 for area under the plasma concentration (AUC) from 0 hour to last time point (AUC0-last) and from 0 hour to infinity (AUC0-inf). The GMR of SY-2101 to ATO IV maximum concentration (Cmax) was 0.76, as was expected due to the different routes of administration. Comparisons of SY-2101 in fed to fasted states demonstrated similar exposure with GMRs of AUC0-last, AUC0-inf, and Cmax at 1.08, 1.12, and 0.85, respectively, allowing for SY-2101 administration with or without food. SY-2101 was well tolerated. Most adverse events were of low grade. This study provides the first intrapatient PK crossover results directly comparing SY-2101 with ATO IV and supports the likelihood of clinical equivalence between the 2 formulations. This trial was registered at www.ClinicalTrials.gov as #NCT04996030.
引用
- Ravandi F, Rangaraju S, Kantarjian H, et al. A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia. Blood Adv. 2025. PMID: 40020161. doi:10.1182/bloodadvances.2024015453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。